Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 4NETWORK 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 3Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Advanced BRAF-mutant Cancers 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
PX-866 × Clear all
NCT01259869 2023-08-22

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

Canadian Cancer Trials Group

Phase 2 Completed
34 enrolled 7 charts
CNS

Glioblastoma

NCT01331083 2023-08-22

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Completed
68 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00726583 2018-05-17

Phase I Trial of Oral PX-866

Seagen Inc.

Phase 1 Completed
90 enrolled

Carcinoma, Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT01204099 2018-05-16

Study of PX-866 and Docetaxel in Solid Tumors

Seagen Inc.

Phase 1/2 Completed
223 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

NCT01616199 2018-05-16

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Seagen Inc.

Phase 1/2 Terminated
24 enrolled

Advanced BRAF-mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡